The recent report by Custom Market Insights highlights significant growth in the application of generative AI within the chemical industry, with market size expected to expand from USD 0.98 billion in 2025 to an estimated USD 12.84 billion by 2035. This growth is fueled by factors such as the need for faster R&D times, rising demand for sustainable molecules, integration with advanced technologies like robotic synthesis and quantum computing, and substantial R&D spending in pharmaceuticals and chemicals. Companies are leveraging AI-generated molecules to enhance drug discovery and chemical innovation, supported by diverse design and optimization capabilities offered by cloud-based and on-premise AI solutions.
Elsewhere in the market, Viavi Solutions was trading firmly up 15.1% and closing at $52.40. Two days ago, the company reported a significant increase in quarterly sales but a decline in net income compared to the previous year. In the meantime, Check Point Software Technologies softened, down 19.6% to end the day at $112.47, close to the 52-week low. Three days ago, Check Point reported a revenue increase to $668.4 million for Q1 2026, with net income slightly rising to $191.6 million.
Explore Check Point Software’s timely growth driven by Quantum Force and Infinity advancement. Click through to delve into the opportunities and challenges shaping its future.
Don’t miss our Market Insights article, “China’s Next Winners,” for a closer look at China’s strategic investments in Cloud AI advancement, crucial for future growth.
Best Cloud AI Stocks
Alphabet ended the day at $384.80 up 10%, not far from its 52-week high. Alphabet reported a significant increase in first-quarter earnings and sales, reported two days ago.
Oracle finished trading at $161.39 down 1.5%.
Microsoft closed at $407.78 down 3.9%. This week, Microsoft reported strong third-quarter earnings growth and announced a collaboration with Richtech Robotics to enhance AI-driven robotic solutions on Azure.
Seize The Opportunity
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
